The aim of this call from JDRF is advancing our understanding of glycaemic changes during disease progression in presymptomatic individuals (Stages 1 and 2), with the potential to improve progression biomarkers and monitoring their transition to clinical diagnosis (Stage 3).
The focus of this call is the improvement of current or new metabolic risk assessment tools and their integration into clinically and commercially utilized testing platforms.
Proposed budgets for projects should not exceed $900,000.00 total costs for up to 3 years of duration.
JDRF will hold an announcement introduction meeting via Zoom on 20 December at 3-4pm GMT. Please register to this webinar using this link.
The deadline for submission of letters of intent is 25 January 2024 , with a full application deadline of 8 March 2024.